# A Study to Compare How Much Solifenacin Succinate and Mirabegron Reach the Blood When Administered Together as Fixed-dose Combination Tablets and With Single Individual Tablets of the Same Medications at Three Dose Levels

> **NCT02010944** · PHASE1 · COMPLETED · sponsor: **Astellas Pharma Europe B.V.** · enrollment: 72 (actual)

## Conditions studied

- Phase 1
- Bioavailability
- Healthy Subjects

## Interventions

- **DRUG:** solifenacin succinate
- **DRUG:** mirabegron
- **DRUG:** mirabegron/solifenacin succinate

## Key facts

- **NCT ID:** NCT02010944
- **Lead sponsor:** Astellas Pharma Europe B.V.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2012-09
- **Primary completion:** 2012-11
- **Final completion:** 2012-11
- **Target enrollment:** 72 (ACTUAL)
- **Last updated:** 2013-12-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02010944

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02010944, "A Study to Compare How Much Solifenacin Succinate and Mirabegron Reach the Blood When Administered Together as Fixed-dose Combination Tablets and With Single Individual Tablets of the Same Medications at Three Dose Levels". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT02010944. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*